Table 7.
Treatment and outcome of the 262 cases of KP bloodstream infection patients.
| Treatment | n (%) | Mortality (%) |
|---|---|---|
| S-KP | 97 (37) | 21 (21.6) |
| Monotherapy | 81 (83.5) | 15 (18.5) |
| Carbapenem | 41 (50.6) | 9 (21.9) |
| Cefoperazone/sulbactam | 20 (24.6) | 4 (20) |
| Piperacillin/tazobactam | 9 (11.1) | 1 (11.1) |
| Ceftazidime | 7 (8.6) | 1 (14.2) |
| Cefepime | 3 (3.7) | 0 |
| Cefminox | 1 (1.2) | 0 |
| Combination therapy | 16 (16.5) | 6 (37.5) |
| Tigecycline + Carbapenem | 2 (12.5) | 1 (50) |
| Tigecycline + Piperacillin/tazobactam | 1 (6.2) | 1 (100) |
| Tigecycline + Carbapenem + Cefoperazone/sulbactam | 1 (6.2) | 0 |
| Carbapenem + Cefoperazone/sulbactam | 6 (37.5) | 3 (50) |
| Carbapenem + Piperacillin/tazobactam | 1 (6.2) | 0 |
| Carbapenem + Ceftazidime | 2 (12.5) | 1 (50) |
| Carbapenem + Cefminox | 1 (6.2) | 0 |
| Piperacillin/tazobactam + Aminoglycosides | 2 (12.5) | 0 |
| MDR-KP | 87 (33.2) | 39 (44.8) |
| Monotherapy | 58 (66.7) | 30 (51.7) |
| Carbapenem | 31 (53.4) | 18 (58) |
| Cefoperazone/sulbactam | 10 (17.2) | 4 (40) |
| Piperacillin/tazobactam | 9 (15.5) | 3 (33.3) |
| Cefepime | 4 (6.8) | 3 (75) |
| Ceftazidime | 2 (3.4) | 1 (50) |
| Cefotiam | 2 (3.4) | 1 (50) |
| Combination therapy | 29 (33.3) | 9 (31) |
| Tigecycline + Carbapenem | 7 (24.1) | 3 (42.8) |
| Tigecycline + Polymyxin B | 1 (3.4) | 0 |
| Tigecycline + Piperacillin/tazobactam | 2 (6.8) | 1 (50) |
| Tigecycline + Aminoglycosides | 5 (17.2) | 1 (20) |
| Tigecycline + Cefoperazone/sulbactam | 1 (3.4) | 1 (100) |
| Tigecycline + Carbapenem + Cefoperazone/sulbactam | 2 (6.8) | 0 |
| Tigecycline + Carbapenem + Aminoglycosides | 1 (3.4) | 0 |
| Carbapenem + Polymyxin B | 1 (3.4) | 1 (100) |
| Carbapenem + Piperacillin/tazobactam | 1 (3.4) | 0 |
| Carbapenem + Cefoperazone/sulbactam | 4 (13.8) | 1 (25) |
| Carbapenem + Ceftazidime | 2 (6.8) | 1 (50) |
| Piperacillin/tazobactam + Aminoglycosides | 2 (6.8) | 0 |
| XDR-KP | 78 (29.7) | 53 (67.9) |
| Monotherapy | 43 (55.1) | 34 (79) |
| Carbapenem | 25 (58.1) | 22 (88) |
| Cefoperazone/sulbactam | 10 (23.2) | 9 (90) |
| Piperacillin/tazobactam | 5 (11.6) | 2 (40) |
| Cefepime | 1 (2.3) | 1 (100) |
| Ceftazidime | 2 (4.6) | 0 |
| Combination therapy | 35 (44.9) | 19 (54.2) |
| Tigecycline + Carbapenem | 11 (31.4) | 7 (63.6) |
| Tigecycline + Polymyxin B | 1 (2.8) | 1 (100) |
| Tigecycline + Piperacillin/tazobactam | 4 (11.4) | 2 (50) |
| Tigecycline + Aminoglycosides | 3 (8.5) | 2 (66.7) |
| Tigecycline + Cefoperazone/sulbactam | 4 (11.4) | 3 (75) |
| Tigecycline + Carbapenem + Cefoperazone/sulbactam | 3 (8.5) | 0 |
| Tigecycline + Carbapenem + Aminoglycosides | 1 (2.8) | 0 |
| Tigecycline + Carbapenem + Polymyxin B | 1 (2.8) | 1 (100) |
| Carbapenem + Cefoperazone/sulbactam | 4 (11.4) | 3 (75) |
| Carbapenem + Aminoglycosides | 1 (2.8) | 0 |
| Carbapenem + Cefepime | 1 (2.8) | 0 |
| Carbapenem + Aminoglycosides + Cefoperazone/sulbactam | 1 (2.8) | 0 |
n sample size, S-KP sensitive K. pneumoniae, MDR-KP multidrug resistant K. pneumoniae, XDR-KP extensively drug resistant K. pneumoniae.